Genprex Receives US FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination with Keytruda^® for the Treatment of Non-Small Cell Lung Cancer

Genprex, Inc. announced that the FDA has granted Fast Track Designation for the Company’s lead drug candidate, REQORSA™ Immunogene Therapy, in combination with Merck & Co’s Keytruda® in patients with histologically-confirmed unresectable stage III or IV non-small cell lung cancer whose disease progressed after treatment with Keytruda.